Publications Repository

Publications Repository

Search 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • Search
  • Home
  • ICR Divisions
  • Clinical Studies
  • Search
JavaScript is disabled for your browser. Some features of this site may not work without it.

Search

Show advanced filtersHide advanced filters

Filters

Use filters to refine the search results.

Now showing items 1-10 of 236

  • Sort Options:
  • Relevance
  • Issue date (newest)
  • Issue date (oldest)
  • Results Per Page:
  • 5
  • 10
  • 20
  • 40
  • 60
  • 80
  • 100
Thumbnail

Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer. 

Welti, J; Rodrigues, DN; Sharp, A; Sun, S; Lorente, D; et al. (2016-10)
Background The androgen receptor splice variant-7 (AR-V7) has been implicated in the development of castration-resistant prostate cancer (CRPC) and resistance to abiraterone and enzalutamide.Objective To develop a validated ...
Thumbnail

Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. 

Evans, JR; Zhao, SG; Chang, SL; Tomlins, SA; Erho, N; et al. (2016-04)
Importance A substantial number of patients diagnosed with high-risk prostate cancer are at risk for metastatic progression after primary treatment. Better biomarkers are needed to identify patients at the highest risk to ...
Thumbnail

Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC). 

Evans, R; Hawkins, N; Dequen-O'Byrne, P; McCrea, C; Muston, D; et al. (SPRINGER, 2021-09-03)
BACKGROUND: In oncology trials, treatment switching from the comparator to the experimental regimen is often allowed but may lead to underestimating overall survival (OS) of an experimental therapy. OBJECTIVE: This study ...
Thumbnail

Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. 

Joshua, AM; Armstrong, A; Crumbaker, M; Scher, HI; de Bono, J; et al. (ELSEVIER SCI LTD, 2022-07-01)
BACKGROUND: Statins and metformin are commonly prescribed for patients, including those with prostate cancer. Preclinical and epidemiologic studies of each agent have suggested anti-cancer properties. METHODS: Patient data ...
Thumbnail

Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. 

Wilson, BE; Armstrong, AJ; de Bono, J; Sternberg, CN; Ryan, CJ; et al. (ELSEVIER SCI LTD, 2022-07-01)
BACKGROUND: The associations of metformin and statins with overall survival (OS) and prostate specific antigen response rate (PSA-RR) in trials in metastatic castration-resistant prostate cancer remain unclear. OBJECTIVE: ...
Thumbnail

Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer. 

Matsubara, N; de Bono, J; Sweeney, C; Chi, KN; Olmos, D; et al. (Elsevier BV, 2023-04-01)
PURPOSE: Adding ipatasertib to abiraterone and prednisone/prednisolone significantly improved radiographic progression-free survival for patients with metastatic castration-resistant prostate cancer (mCRPC) with PTEN-loss ...
Thumbnail

A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer. 

Macaulay, VM; Lord, S; Hussain, S; Maroto, JP; Jones, RH; et al. (SPRINGERNATURE, 2023-10-05)
BACKGROUND: This multicentre, open-label, Phase Ib/II trial evaluated the insulin-like growth factor (IGF) 1/2 neutralising antibody xentuzumab plus enzalutamide in metastatic castrate-resistant prostate cancer (mCRPC). ...
Thumbnail

A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies. 

Juric, D; de Bono, JS; LoRusso, PM; Nemunaitis, J; Heath, EI; et al. (2017-09)
Purpose: To evaluate the safety, MTD, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of TAK-117 (MLN1117/INK1117), an investigational PI3Kα-selective inhibitor, in patients with advanced solid tumors. ...
Thumbnail

Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study. 

de Wit, R; Wülfing, C; Castellano, D; Kramer, G; Eymard, J-C; et al. (ELSEVIER, 2021-08-24)
BACKGROUND: There is growing evidence that a high neutrophil-to-lymphocyte ratio (NLR) is associated with poor overall survival (OS) for patients with metastatic castration-resistant prostate cancer (mCRPC). In the CARD ...
Thumbnail

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. 

Zucali, PA; Lin, C-C; Carthon, BC; Bauer, TM; Tucci, M; et al. (BMJ PUBLISHING GROUP, 2022-01-01)
BACKGROUND: Preclinical data suggest that concurrent treatment of anti-CD38 and antiprogrammed death 1 (PD-1)/programmed death ligand 1 (PD-L1) antibodies substantially reduce primary tumor growth by reversing T-cell ...
  • «
  • 1
  • 2
  • 3
  • 4
  • . . .
  • 24
  • »

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types

Discover

Author
De Bono, Johann (236)
Carreira, Suzanne (47)Banerji, Udai (37)Sharp, Adam (36)Rescigno, Pasquale (35)... View MoreSubjectHumans (159)Male (137)Aged (68)Prostatic Neoplasms, Castration-Resistant (67)Middle Aged (65)... View MoreDate Issued2020 - 2023 (88)2010 - 2019 (144)2004 - 2009 (3)Publication TypeJournal Article (232)Other (4)
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.